Intrommune Therapeutics Announces Publication of OMEGA Study in Peanut Allergic Adults in Annals of Allergy, Asthma & Immunology
Groundbreaking Study Demonstrates Safety and Tolerability of Oral Mucosal Immunotherapy (OMIT) for Peanut Allergy Using Toothpaste
NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- The global burden of food allergy has increased exponentially over the past few decades and represents a significant health concern. In the United States alone, an estimated 33 million individuals are affected by food allergies with peanut allergy being one of the most prevalent, persistent and severe food allergies. With only two FDA approved treatments, the cornerstone of management requires complete avoidance of the food allergen and the use of rescue medication. This presents significant challenges for food allergic individuals due to the ongoing risk of accidental exposure, underscoring a critical unmet need for effective and convenient treatments.
Today, Intrommune Therapeutics, Inc. is excited to announce the publication of a its Phase 1 OMEGA (Oral Mucosal Escalation Goal Assessment) study evaluating the safety, tolerability, and adherence of a novel toothpaste-based treatment for peanut allergy in adults. Intrommune's proprietary Oral Mucosal Immunotherapy (OMIT) platform using INT301, a customized peanut protein, stabilized and embedded within a fully functional toothpaste. The principal mechanism involves administering OMIT with INT301 directly to the oral cavity using toothpaste as the delivery vehicle which facilitates consistent and targeted immune exposure to peanut allergen, a key requirement for effective desensitization.
The randomized, placebo-controlled trial, published in the prestigious Annals of Allergy, Asthma & Immunology, marks a significant advancement in food allergy immunotherapy and highlights the potential for OMIT to transform the landscape of peanut allergy treatment through the simple act of toothbrushing. The study, titled a "Randomized, Placebo-Controlled, Phase 1 Safety Study of Oral Mucosal Immunotherapy in Peanut Allergic Adults," enrolled 32 peanut-allergic adults and assessed the safety and tolerability of increasing amounts of INT301 toothpaste. The findings demonstrated that OMIT with INT301 achieved an exceptional safety profile, with 100% of participants tolerating the highest dose they received. Encouragingly, there were no reports of anaphylaxis or severe systemic reactions in any of the treated participants and none of the study participants opted to withdraw from the study due to this novel treatment. Moreover, the non-systemic reactions that did occur were mostly mild, transient and localized to the mouth and lips. The robust safety profile coupled with an adherence rate of 97%, illustrates the patient-centric nature of this innovative approach.
'These findings represent a major step forward in our mission to develop patient-centered products for use in preventing and treating food allergies,' stated Michael Nelson, CEO at Intrommune Therapeutics. 'The remarkable safety, tolerability, and adherence profile observed in the OMEGA trial elevates the potential of OMIT as a safe and convenient treatment option for individuals with peanut allergy.' Encouraged by these positive findings, Intrommune Therapeutics is committed to evaluating both the safety and efficacy of the OMIT platform in a larger trial of pediatric subjects with peanut and tree nut allergies.
Read a ' here: https://www.annallergy.org/article/S1081-1206(25)00040-7/fulltext
About Intrommune Therapeutics: Intrommune Therapeutics is dedicated to developing innovative and patient-friendly products for use in preventing and treating food allergies. The company's proprietary Oral Mucosal Immunotherapy (OMIT) platform aims to revolutionize food allergy treatment by delivering allergenic proteins through a convenient toothpaste, targeting the oral mucosa for desensitization. Intrommune is committed to improving the lives of millions affected by food allergies worldwide.
Contact:Nicole FarisIntrommune Therapeuticsnfaris@intrommune.com +1-206-499-3779
Cautionary Statement Regarding Forward Looking Statements
This release may contain 'forward-looking statements.' Forward-looking statements are identified by certain words or phrases such as 'may,' 'will,' 'aim,' 'will likely result,' 'believe,' 'expect,' 'will continue,' 'anticipate,' 'estimate,' 'intend,' 'plan,' 'contemplate,' 'seek to,' 'future,' 'objective,' 'goal,' 'project,' 'should,' 'will pursue' and similar expressions or variations of such expressions. These forward-looking statements reflect the company's current expectations about its future plans and performance. These forward-looking statements rely on a number of assumptions and estimates which could be inaccurate and which are subject to risks and uncertainties. Actual results could vary materially from those anticipated or expressed in any forward-looking statement made by the company. The company disclaims any obligation or intent to update the forward-looking statements in order to reflect events or circumstances after the date of this release.
This release does not contain or constitute an offer to sell or a solicitation of any offer to buy securities in the United States or in any other jurisdiction.Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Chicago Tribune
41 minutes ago
- Chicago Tribune
Jim Taylor: What my wife's experience with Alzheimer's has taught me
After several unexplained memory slips, there came a day when my wife, Geri, didn't recognize her own face in the mirror. That's when we knew it was time for her to get checked out. It was 2012, and Alzheimer's was a feared diagnosis. At the time, billions of dollars of investments into research and development had failed to produce treatments that could prevent, slow or cure the disease. Getting a definitive diagnosis would be extremely difficult, but the alternative was living with years of the landscape for Alzheimer's diagnosis and treatment has taken a great leap forward. It is increasingly possible to manage the disease and live a fulfilling life. We have reached a historic moment with the FDA's approval of the first blood biomarker tests for Alzheimer's. This long-awaited breakthrough means physicians can now detect early signs of Alzheimer's — which accounts for 70% of all cases of dementia — using a simple blood test that can be done during a regular check-up with your PET scans remain important for confirming a diagnosis, they are only available at specialized centers, typically in urban medical centers, and they are expensive. Blood biomarker tests now offer an easy first step in the diagnostic journey. They provide fast answers for people experiencing memory problems and can even spot early signs of cognitive decline years before symptoms appear. Without these tests, most people have a long, challenging path to wife Geri's path to diagnosis was anything but simple. In 2012, a neurologist confirmed she had mild cognitive impairment, a common precursor to Alzheimer's. It was a life-altering event. Over the next few years, we knew we had to dig deeper into the cause of her condition, to uncover any potential medical options. Eventually we found a clinical trial for an experimental Alzheimer's drug, and she received a PET scan to determine whether she qualified for the trial. Her brain scan detected amyloid plaque, the telltale sign of Alzheimer's. The diagnosis was difficult to face, but it meant we didn't have to struggle with uncertainty. We could act.I understand the fear that surrounds an Alzheimer's diagnosis, but catching it early helps. Changes in the brain begin years before memory problems become noticeable. The earlier the diagnosis, the more options people have. Research shows that anti-amyloid therapies are more effective when administered earlier: In one clinical trial, patients with early Alzheimer's showed 35% slowing of cognitive decline, compared with those on the placebo. These treatments can help people maintain their independence longer and make the most of their lucid was fortunate to participate in a clinical trial that significantly slowed her disease progression. The seven-year trial period was a game-changer for us. The regular infusions were a source of hope as we saw her benefit from the medication. This precious time allowed Geri to develop coping strategies to manage her disease. Together, we traveled across the country giving talks about living with Alzheimer's disease, and Geri needed very little assistance. We cherished this time together — years made possible because we sought answers early. Following the FDA's landmark approval of blood biomarker tests, the next step is making these tests widely available. Hospitals and health care systems across the country should ensure primary care physicians are aware of these tests and understand how to use them. Public education campaigns can raise awareness with people who have concerns about cognitive impairment and their detection gives people meaningful choices, and most importantly it gives people time. Time to benefit from lifestyle changes, participate in groundbreaking clinical trials, and access treatments when they can make the greatest difference. Although facing a potential Alzheimer's diagnosis is daunting, waiting only limits a person's options. If you're concerned that you or a loved one might have signs of cognitive impairment, please don't stay in the dark. Blood biomarker tests offer real hope in a new era of Alzheimer's care. The sooner we embrace these advances, the more precious time we can preserve.
Newsweek
3 hours ago
- Newsweek
Dr Pepper Recall Issued After Sugar Mix Up in Thousands of Cans
A recall has been issued for thousands of cases of Dr Pepper Zero Sugar that were mislabeled and contained the full-sugar product, according to the U.S. Food and Drug Administration (FDA). The products were distributed to retailers in Florida, Georgia, and South Carolina. Newsweek contacted Keurig Dr Pepper, which owns the product in the United States, and PepsiCo, which bottled the beverages, for comment via email outside of regular working hours. Why It Matters This mislabeling poses potential health risks to consumers, particularly for individuals managing conditions like diabetes or those monitoring their sugar intake The FDA has issued a Class II risk classification for the recall, indicating that the consumption of the mislabeled products may cause temporary or medically reversible adverse health consequences. What To Know The FDA said the company-initiated recall affects 19,203 cases of Dr Pepper Zero Sugar 12-fluid ounce cans, sold in 12-pack and 24-pack cartons. The affected cans were produced at a Pepsi bottling facility in Jacksonville, Florida, which is licensed to manufacture Keurig Dr Pepper products, according to the FDA. The affected products have the product code XXXXRS05165, and a best-by date of February 16, 2026. The recall was initiated on May 23, 2025, and the FDA classified it as a Class II recall on June 5, 2025. A can of regular Dr Pepper contains 39 grams of sugar, while the Zero Sugar version has zero grams, but contains the artificial sweeteners aspartame and acesulfame potassium. There were 241 FDA food and beverage recalls in 2024, which was an increase of eight percent from the previous year, according to a report published by the nonprofit Public Interest Research Group. Undeclared allergens or ingredients was the single biggest cause for recalls that year. Last year, Dr Pepper tied with Pepsi to become the second most popular soda in the U.S. after Coca Cola, according to data from Beverage Digest. What Happens Next The FDA and Dr Pepper are working to ensure that all affected products are removed from store shelves promptly. Consumers in the affected states should remain vigilant and check their purchases to ensure they have not bought the mislabeled product.
Yahoo
11 hours ago
- Yahoo
FDA Reveals Which Kinds of Eggs May Be Contaminated with Salmonella
In a June news release, the U.S. Food and Drug Administration revealed that "brown cage-free and brown certified organic eggs" from the August Egg Company have "the potential" to be contaminated with salmonella. The outlet added that the eggs were "sold under multiple different brand names at restaurants and retailers" and should "no longer be available for sale." Those brands are Clover, First Street, Nuaid, O Organics, Marketside, Raleys, Simple Truth, Sun Harvest, and Sunnyside. According to People, over 1.7 million eggs have been recalled in nine states: California, Washington, Nevada, Arizona, Wyoming, New Mexico, Nebraska, Indiana, and Illinois. On June 6, 2025, the Centers for Disease Control and Prevention revealed they were investigating the "multi-state outbreak of salmonella infections." Mayo Clinic states that while some people with salmonella may have no symptoms, most experience a range of symptoms, like abdominal cramps, within 8 to 72 hours. "In some cases, diarrhea can cause severe dehydration and requires prompt medical attention. Life-threatening complications also may develop if the infection spreads beyond the intestines. The risk of getting salmonella infection is higher with travel to countries without clean drinking water and proper sewage disposal." At this time, 21 people have been hospitalized due to infection, according to the FDA. In a statement, the August Egg Company shared, "We believe it is appropriate out of an abundance of caution to conduct this voluntary recall, as consumers may still have these eggs in their homes. It is important to know that when our processing plant identified this concern, we immediately began diverting all eggs from the plant to an egg-breaking facility, which pasteurizes the eggs and kills any pathogens." The company concluded, "We are committed to addressing this matter fully and to implementing all necessary corrective actions to ensure this does not happen again."FDA Reveals Which Kinds of Eggs May Be Contaminated with Salmonella first appeared on Men's Journal on Jun 7, 2025
